Literature DB >> 16387930

Effect of clarithromycin on rhinovirus-16 infection in A549 cells.

Y J Jang1, H-J Kwon, B-J Lee.   

Abstract

Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection. The effect of CM on RV infection in A549 cells was therefore investigated. Cells were pre-treated with 1, 10 or 100 microM CM, either starting 3 days before infection and continuing thereafter, or by addition at the time of infection. RV titre, as measured by culture on Medical Research Council 5 cells, was reduced by CM, with the degree of reduction being greater when CM was added 3 days before infection than when it was added at the time of infection. CM treatment inhibited the RV-induced increase in ICAM-1 mRNA and protein, as well as the RV-induced secretion of IL-1beta, IL-6, and IL-8. These effects were greater in cells treated with 10 microM than in those treated with 100 microM CM, and the maximum effect was observed 3 days after viral infection. In contrast, secretion of IL-8 was not inhibited significantly when CM was added at the time of viral infection. The findings of this study suggest that, in A549 cells, clarithromycin inhibits the induction of intercellular adhesion molecule-1 expression, cytokine elaboration, and viral infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16387930     DOI: 10.1183/09031936.06.00008005

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

1.  Comparison of rhinovirus A infection in human primary epithelial and HeLa cells.

Authors:  S P Amineva; A G Aminev; J E Gern; A C Palmenberg
Journal:  J Gen Virol       Date:  2011-07-13       Impact factor: 3.891

Review 2.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  [Efficacy of clarithromycin in the adjuvant treatment of chronic periodontitis: a Meta-analysis].

Authors:  Yin Bai; Yuan-Liang Bai; Jing Lai; Jiao Huang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

Review 4.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

5.  Fosfomycin suppresses chemokine induction in airway epithelial cells infected with respiratory syncytial virus.

Authors:  Tamaki Okabayashi; Shin-ichi Yokota; Yuko Yoto; Hiroyuki Tsutsumi; Nobuhiro Fujii
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

Review 6.  Macrolide therapy in respiratory viral infections.

Authors:  Jin-Young Min; Yong Ju Jang
Journal:  Mediators Inflamm       Date:  2012-06-06       Impact factor: 4.711

7.  Clarithromycin suppresses human respiratory syncytial virus infection-induced Streptococcus pneumoniae adhesion and cytokine production in a pulmonary epithelial cell line.

Authors:  Shin-ichi Yokota; Tamaki Okabayashi; Satoshi Hirakawa; Hiroyuki Tsutsumi; Tetsuo Himi; Nobuhiro Fujii
Journal:  Mediators Inflamm       Date:  2012-06-12       Impact factor: 4.711

8.  The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells.

Authors:  Nadine Lusamba Kalonji; Kazuhiro Nomura; Tetsuaki Kawase; Chiharu Ota; Hiroshi Kubo; Takeya Sato; Teruyuki Yanagisawa; Toshiaki Sunazuka; Satoshi Ōmura; Mutsuo Yamaya
Journal:  Physiol Rep       Date:  2015-10

9.  Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients.

Authors:  Mandy Menzel; Hamid Akbarshahi; Leif Bjermer; Lena Uller
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

Review 10.  Macrolide therapy in chronic inflammatory diseases.

Authors:  Brygida Kwiatkowska; Maria Maślińska
Journal:  Mediators Inflamm       Date:  2012-08-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.